Navigation Links
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
Date:8/7/2008

ts are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. These and other risks are described in greater detail in our Annual Report on Form 10-K for the year ended December 31, 2007, and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward looking statements because of these uncertainties, and the inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. We assume no obligation to update forward looking statements. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

CONTACTS:

Investors: Media

John Quirk Cory Tromblee, both of

Porter Novelli Life Sciences Porter Novelli Life Sciences

(212) 601-8296
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
3. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
9. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
10. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
11. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... LONDON , March 27, 2015 ... commercial prospects for leading ophthalmic drug companies  ... the pharma ophthalmic industry ? Visiongain,s brand new ... trends, opportunities and prospects there. Our 242-page ... most lucrative areas in the industry and the future ...
(Date:3/27/2015)... Wis. , March 27, 2015 ... unit shipments of incontinence devices for women. ... but the most gratifying part is the hundreds ... from women whose lives have been positively impacted ... president of InControl. InControl recently released ...
(Date:3/27/2015)... MARLBOROUGH, Mass. , March 27, 2015 ... ) and privately-held MirImmune LLC, today announced ... license agreement to RXi,s novel and proprietary ... cell-based cancer immunotherapies. The collaboration has the ... and patient friendly cancer treatments that could ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
... , , , ... Now in its 9th year, the ePharma,Summit ( ... at Penn,s Landing, Philadelphia, PA ,continues to be ... after,year, hundreds of marketing professionals from leading pharmaceutical,companies attend ePharma ...
... , ST. LOUIS , Jan. 27 ... 510 (k) clearance from the U.S. Food and Drug Administration ... device linking patients and doctors between eye exams for ongoing ... but brief exam on their ForeseeHome AMD Monitor, in the ...
Cached Medicine Technology:MarketsandMarkets Partners with the 9th Annual ePharma Summit to be Held on February 8 -10, 2010 2MarketsandMarkets Partners with the 9th Annual ePharma Summit to be Held on February 8 -10, 2010 3Notal Vision's ForeseeHome(TM) AMD Monitor Receives FDA Clearance 2
(Date:3/29/2015)... “Health is an endo thing, from ... more about the cannabinoid system … we learn it’s ... Go Endo-Cannabinoid Update ~ new on the Bryan ... Publius, of The Cannabis Papers: A citizen’s guide to ... (PubMed) cannabinoid system (CS) articles discussing: cannabinoids in the ...
(Date:3/28/2015)... a bite of warm, gooey pepperoni pizza, and your ... stomach, ready to break down your meal. In many ... amok, triggering a burning sensation in the chest. Heartburn ... Americans have heartburn at least once a month. The ... can be stopped. , Heartburn or acid reflux symptoms ...
(Date:3/28/2015)... FL (PRWEB) March 28, 2015 ... conditions coverage is made available to all visitors who ... effective immediately. All members are encouraged to purchase the ... to avoid lack of proper coverage for pre-existing medical ... from one or two medical conditions with serious consequences ...
(Date:3/28/2015)... How best to treat and recover ... orthopaedic medicine. While diagnostic hip injections are commonly performed ... etiology, research presented today at the American Orthopaedic Society ... that pain relief from this diagnostic injection may not ... “Our study looked to assess if the amount of ...
(Date:3/28/2015)... Lately the student-athlete experience has ... proposals around the NCAA. In a March episode of ... across a spectrum of universities and sports shed light ... special panel consists of athletes who have competed for ... track and field, baseball, and volleyball. They discuss the ...
Breaking Medicine News(10 mins):Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3
... Delhi: The eradication of neglected tropical diseases should be ... World Health Organization (WHO).// ,Many people in ... lymphatic filaria, leishmaniasis and yaws. Dengue is emerging as ... diseases cause great suffering and ill-health and have considerable ...
... - A new study by researchers from Queen's University ... eye movement tests in the diagnosis of fetal alcohol ... called FASD affects children when mothers have consumed alcohol ... tasks, could help effectively measure FASD in children, the ...
... government has approved meat and milk from cloned animals while ... Thursday that its customers and consumers don't want milk from ... Horizon Organic, among dozens of other brands. ... buying dairy products that contain milk from cloned cows and ...
... from a variety of backgrounds and locales have been ... Adams Quality of Life Award, a prestigious national prize ... Award recognizes individuals who have made a difference through ... care, and counsel to persons living with cancer and ...
... and child-care groups are calling on the Federal Government to ... stomach bugs. ,Rotavirus puts 10,000 Australian children in ... emergency wards and at doctors' surgeries with symptoms of acute ... given to children aged six to 32 weeks, is only ...
... The African Malaria Network Trust (AMANET) has received a ... & Melinda Gates// Foundation. ,According to the ... the four-year grant is aimed at strengthening institutional capacity ... ,It also aims at fostering and promoting discussion, ...
Cached Medicine News:Health News:WHO Urges Higher Priority for Neglected Diseases 2Health News:Milk from Cloned Cows is Not Welcome at the Nation's Biggest Milk Company 2Health News:American Cancer Society Honors Exemplary Cancer Caregivers 2Health News:Call for Rotavirus Vaccine Funding 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: